FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC (FORTIFI-HN01)

October 28, 2026 updated by: Bicara Therapeutics

A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β).

This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The mechanism of action of ficerafusp alfa involves dual targeting of two cancer targets, EGFR and TGF-β, which are known to drive solid tumor growth and metastasis.

Phase 2 of the study will identify an optimal biologic dose (OBD) supported by the safety, tolerability, PK, PD, and efficacy data of ficerafusp alfa. In this part, eligible subjects will be randomized to one of three treatment arms at a 1:1:1 ratio:

  • Arm A: ficerafusp alfa 1500 mg once weekly (QW) + pembrolizumab 200 mg every three weeks (Q3W).
  • Arm B: ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W.
  • Arm C (control): placebo QW + pembrolizumab 200 mg Q3W.

The primary objective for the phase 3 portion is to compare the efficacy in subjects treated with ficerafusp alfa at the selected OBD in combination with pembrolizumab versus placebo with pembrolizumab. Eligible subjects will be randomized 2:1 in the treatment versus control arm during the phase 3 portion.

Study Type

Interventional

Enrollment (Estimated)

650

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Buenos Aires, Argentina, C1190
      • Buenos Aires, Argentina, C1425
      • Pilar, Argentina, B1629ODT
        • Recruiting
        • Hospital Universitario Austral (Site # 2303)
        • Contact:
      • Rosario, Argentina, CP2000
        • Recruiting
        • Sanatorio de la Mujer (Site # 2305)
        • Contact:
      • Santa Fe, Argentina, S2002KDT
        • Recruiting
        • Hospital Provincial del Centenario (Site # 2302)
        • Contact:
    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • Recruiting
        • Chris O'Brien Lifehouse (Site#0302)
        • Contact:
      • Kingswood, New South Wales, Australia, 2747
      • Waratah, New South Wales, Australia, 2298
        • Recruiting
        • Calvary Mater Newcastle (Site#0304)
        • Contact:
    • Queensland
      • Southport, Queensland, Australia, 4215
        • Recruiting
        • Gold Coast University Hospital (Site #0305)
        • Contact:
      • Tugun, Queensland, Australia, 4224
        • Recruiting
        • John Flynn Private Hospital (Site#0307)
        • Contact:
    • Victoria
      • Heidelberg, Victoria, Australia, 3084
      • North Melbourne, Victoria, Australia, 3051
        • Recruiting
        • Peter Macallum Cancer Centre (Site#0301)
        • Contact:
    • Western Australia
      • Murdoch, Western Australia, Australia, 6150
        • Recruiting
        • Fiona Stanley Hospital (Site#0308)
        • Contact:
      • Salzburg, Austria, 5020
        • Recruiting
        • Hematology and Medical Oncology, Paracelsus Medical University (Site #1602)
        • Contact:
      • Vienna, Austria, 1090
        • Recruiting
        • Medical University Vienna (Site #1601)
        • Contact:
      • Bruges, Belgium, 8000
        • Recruiting
        • AZ St-Jan Brugge Oostende av (Campus Sint-Jan) (Site #1007)
        • Contact:
      • Mons, Belgium, 7000
      • Namur, Belgium, 5000
        • Recruiting
        • CHU UCL Namur, Site Ste. Elisabeth (Site #1002)
        • Contact:
      • Namur, Belgium, 5530
        • Recruiting
        • CHU UCL Namur, Site Mont-Godinne (Site #1003)
        • Contact:
      • Sint-Niklaas, Belgium, 9100
      • Wilrijk, Belgium, 2610
      • Barretos, Brazil, 14784-400
        • Recruiting
        • Hospital de Amor de Barretos - Fundação Pio XII (Site # 2413)
        • Contact:
      • Belém, Brazil, 66063495
        • Recruiting
        • Centro de Tratamento Oncologico (Site # 2421)
        • Contact:
      • Curitiba, Brazil, 80810-050
        • Recruiting
        • CIONC-Centro Integrado de Oncologia de Curitiba (Site # 2404)
        • Contact:
      • Fortaleza, Brazil, 60430235
        • Recruiting
        • Hospital Haroldo Juaçaba - Instituto do Câncer do Ceará (Site # 2414)
        • Contact:
      • Ijuí, Brazil, 98700-000
        • Recruiting
        • Oncosite - Centro de Pesquisa Clinica e Oncologia (Site # 2402)
        • Contact:
      • Jaú, Brazil, 17210-120
        • Recruiting
        • Fundação Doutor Amaral Carvalho (Site # 2411)
        • Contact:
      • Natal, Brazil, 59062-000
        • Recruiting
        • Liga Norte-Rio-Grandense Contra o Câncer (Site # 2422)
        • Contact:
      • Passo Fundo, Brazil, 99010-260
        • Recruiting
        • Hospital de Clínicas de Passo Fundo (Site # 2419)
        • Contact:
      • Porto Alegre, Brazil, 91350-200
        • Recruiting
        • Hospital Nossa Senhora da Conceicao (Site # 2403)
        • Contact:
      • Rio de Janeiro, Brazil, 22250-905
        • Recruiting
        • Grupo Oncoclínicas (Site # 2412)
        • Contact:
      • Santa Cruz do Sul, Brazil, 96835-100
      • Santa Lúcia, Brazil, 30360680
        • Recruiting
        • Oncoclinicas do Brasil Serviços Médicos S.A - Oncocentro BH (Site # 2401)
        • Contact:
      • São Caetano do Sul, Brazil, 09541-270
        • Recruiting
        • Centro de Oncologia do ABC - Unidade Santo Andre (Site # 2410)
        • Contact:
      • São José do Rio Preto, Brazil, 15090-000
        • Recruiting
        • Centro Integrado de Pesquisa do Hospital de Base de São José do Rio Preto/FUNFAR (Site # 2406)
        • Contact:
      • São Paulo, Brazil, 01246-000
        • Recruiting
        • Instituto do Cancer do Estado de Sao Paulo (ICESP) (Site # 2417)
        • Contact:
      • São Paulo, Brazil, 01509-900
        • Recruiting
        • A. C. Camargo Cancer Center (Site # 2409)
        • Contact:
      • São Paulo, Brazil, 04014-002
        • Recruiting
        • IBCC Núcleo de Pesquisa e Ensino (Site # 2405)
        • Contact:
      • São Paulo, Brazil, 04543
        • Recruiting
        • Oncoclínicas - SP (Site # 2416)
        • Contact:
      • São Paulo, Brazil, 08270-120
        • Recruiting
        • Hospital Santa Marcelina (Site # 2418)
        • Contact:
    • Vitoria ES
      • Santa Cecília, Vitoria ES, Brazil, 29043-260
        • Recruiting
        • AFECC Hospital Santa Rita de Cassia (Site # 2420)
        • Contact:
      • Toronto, Canada, M4N 3M5
        • Recruiting
        • Sunnybrook Health Sciences Centre (Site # 0204)
        • Contact:
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 4E6
        • Recruiting
        • BC Cancer - Vancouver (Site #0202)
        • Contact:
    • Quebec
      • Montreal, Quebec, Canada, H2X 0C1
        • Recruiting
        • Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopital Notre-Dame (Site #0203)
        • Contact:
      • Hradec Králové, Czechia, 500 03
        • Recruiting
        • Fakultni Nemocnice Hradec Kralove (FNHK) (Site # 2101)
        • Contact:
      • Prague, Czechia, 15006
        • Recruiting
        • Fakultni nemocnice Motol a Homolka (Site #2102)
        • Contact:
      • Amiens, France, 80480
        • Recruiting
        • CHU Amiens - Hopital Sud (Site #0809)
        • Contact:
      • Bordeaux, France, 33075
      • Lille, France, 59000
        • Recruiting
        • Centre Oscar Lambret (Site # 0804)
        • Contact:
      • Lyon, France, 69004
        • Recruiting
        • Centre Hospitalier de la Croix Rousse (Site #0810)
        • Contact:
      • Paris, France, 75005
        • Recruiting
        • Institut Curie - site de Paris (Site # 0813)
        • Contact:
      • Rennes, France, 35042
        • Recruiting
        • CRLCC Eugene Marquis (Site #0805)
        • Contact:
      • Saint-Grégoire, France, 35760
        • Recruiting
        • Les Hopitaux Prives Rennais - Saint-Gregoire (Site #0807)
        • Contact:
      • Strasbourg, France, 67200
        • Recruiting
        • Centre Regional Lutte Contre Le Cancer - PAUL STRAUSS (Site #0808)
        • Contact:
      • Toulouse, France, 31059
      • Vandœuvre-lès-Nancy, France, 54519
        • Recruiting
        • ICL - Alexis Vautrin (Site #0806)
        • Contact:
      • Villejuif, France, 94805
        • Recruiting
        • Institut Gustave Roussy (Site #0801)
        • Contact:
      • Aachen, Germany, 52074
        • Recruiting
        • Universitaetsklinikum Aachen AOeR (Site #0710)
        • Contact:
      • Berlin, Germany, 12200
        • Recruiting
        • Charite - Campus Benjamin Franklin (Site # 0701)
        • Contact:
      • Berlin, Germany, 12351
        • Recruiting
        • Vivantes Klinikum Neukoelln (Site # 0714)
        • Contact:
      • Braunschweig, Germany, 38114
        • Recruiting
        • Staedtisches Klinikum Braunschweig gGmbH (Site # 0709)
        • Contact:
      • Chemnitz, Germany, 09116
        • Recruiting
        • Klinikum Chemnitz gGmbH (Site # 0705)
        • Contact:
      • Dresden, Germany, 01067
        • Recruiting
        • Staedtisches Klinikum Dresden Standort Dresden-Friedrichstadt (Site #0707)
        • Contact:
      • Dresden, Germany, 01307
        • Recruiting
        • Universitaetsklinikum Carl Gustav Carus TU Dresden (Site # 0711)
        • Contact:
      • Düsseldorf, Germany, 40225
        • Recruiting
        • Heinrich-Heine-Universitaet Duesseldorf (Site #0706)
        • Contact:
      • Essen, Germany, 45147
        • Recruiting
        • Universitaetsklinikum Essen (Site # 0716)
        • Contact:
      • Göttingen, Germany, 37075
        • Recruiting
        • Universitaetsmedizin Goettingen (Site # 0708)
        • Contact:
      • Hanover, Germany, 30625
        • Recruiting
        • Medizinische Hochschule Hannover (Site # 0718)
        • Contact:
      • Karlsruhe, Germany, 76137
        • Recruiting
        • Vincentius-Diakonissen-Kliniken gAG/St. Vincentius-Kliniken (Site #0717)
        • Contact:
      • München, Germany, 81675
        • Recruiting
        • Technische Universität München School of Medicine (Site # 0715)
        • Contact:
      • Stuttgart, Germany, 70174
        • Recruiting
        • Klinikum Stuttgart-Katharinenhospital (Site # 0703)
        • Contact:
      • Ulm, Germany, 89075
        • Recruiting
        • Universitaetsklinikum Ulm (Site # 0702)
        • Contact:
      • Athens, Greece, 12461
        • Recruiting
        • U.G.H. ATTIKON - General Hospital of West Attica "H AGIA VARVARA" (Site # 1701)
        • Contact:
      • Larissa, Greece, 41110
        • Recruiting
        • University General Hospital of Larissa (Site # 1702)
        • Contact:
      • Madurai, India, 625107
        • Recruiting
        • Meenakshi Mission Hospital & Research Centre (Site # 3003)
        • Contact:
      • Sūrat, India, 395004
      • Cork, Ireland, T12 DC4A
        • Recruiting
        • Cork University Hospital - Consultants Private Clinic (Site # 0603)
        • Contact:
      • Dublin, Ireland, D08 NHY1
        • Recruiting
        • Trinity College Dublin (TCD) - St. James's Hospital (SJH) (Site #0602)
        • Contact:
      • Dublin, Ireland, D09 V2N0
      • Beersheba, Israel, 84101
        • Recruiting
        • Soroka Medical Center (Site # 1901)
        • Contact:
      • Jerusalem, Israel, 9112001
        • Recruiting
        • Hadassah Medical Center (Site # 1903)
        • Contact:
      • Petah Tikva, Israel, 49100
        • Recruiting
        • Rabin Medical Center (Site # 1904)
        • Contact:
      • Tel Aviv, Israel, 6423906
        • Recruiting
        • Sourasky Medical Center (Site # 1902)
        • Contact:
      • Bologna, Italy, 40138
        • Recruiting
        • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi (Site #0904)
        • Contact:
      • Cagliari, Italy, 09121
      • Florence, Italy, 50134
        • Recruiting
        • Azienda Ospedaliera Universitaria Careggi (Site #0911)
        • Contact:
      • Milan, Italy, 20132
        • Recruiting
        • Ospedale San Raffaele (Site #0907)
        • Contact:
      • Milan, Italy, 20133
        • Recruiting
        • Fondazione IRCCS Istituto Nazionale dei Tumori (Site #0901)
        • Contact:
      • Milan, Italy, 20142
        • Recruiting
        • ASST Santi Paolo e Carlo, Ospedale San Paolo Polo Universitario (Site #0905)
        • Contact:
      • Milan, Italy, 20162
        • Recruiting
        • Azienda Socio Sanitaria Territoriale Niguarda (Site # 0912)
        • Contact:
      • Naples, Italy, 80131
        • Recruiting
        • Istituto Nazionale Tumori Fondazione G. Pascale (Site #0915)
        • Contact:
      • Naples, Italy, 80131
        • Recruiting
        • UOC Oncoematologia AOU - University Luigi Vanvitelli (Site # 0916)
        • Contact:
      • Padova, Italy, 35128
        • Recruiting
        • IOV - Istituto Oncologico Veneto IRCCS (Site # 0910)
        • Contact:
      • Palermo, Italy, 90127
        • Recruiting
        • Policlinico P. Giaccone di Palermo (Site #0908)
        • Contact:
      • Pavia, Italy, 27100
        • Recruiting
        • Fondazione IRCCS Policlinico San Matteo (Site # 0903)
        • Contact:
      • Pisa, Italy, 56126
        • Recruiting
        • Azienda Ospedaliero Universitaria Pisana (Site # 0909)
        • Contact:
      • Rome, Italy, 00161
        • Recruiting
        • Azienda Ospedaliero-Universitaria Policlinico Umberto I (Site #0917)
        • Contact:
      • Rome, Italy, 00168
        • Recruiting
        • Fondazione Policlinico Universitario - Agostino Gemelli (Site #0918)
        • Contact:
      • Rome, Italy, 00186
        • Recruiting
        • Fatebenefratelli Isola Tiberina, Gemelli Isola (Site #0906)
        • Contact:
      • Rozzano, Italy, 20089
        • Recruiting
        • Humanitas Mirasole S.p.A (Site # 0919)
        • Contact:
      • Siena, Italy, 53100
        • Recruiting
        • A.O.U. Senese Policlinico Santa Maria alle Scotte (Site # 0902)
        • Contact:
      • Kōtoku, Japan, 135-8550
        • Recruiting
        • Cancer Institute Hospital of JFCR (Site # 3107)
        • Contact:
      • George Town, Malaysia, 11200
        • Recruiting
        • Mount Miriam Cancer Hospital (Site # 2802)
        • Contact:
      • Kuala Lumpur, Malaysia, 50586
        • Recruiting
        • Hospital Kuala Lumpur (Site # 2803)
        • Contact:
      • Kuala Lumpur, Malaysia, 59100
        • Recruiting
        • University Malaya Medical centre (Site # 2805)
        • Contact:
      • Kuching, Malaysia, 93200
        • Recruiting
        • Sarawak General Hospital (Site # 2801)
        • Contact:
      • Pulau Pinang, Malaysia, 10450
        • Recruiting
        • Hospital Pulau Pinang (Site # 2804)
        • Contact:
      • Christchurch, New Zealand, 8011
        • Recruiting
        • Christchurch Hospital NZ (Site #0401)
        • Contact:
      • Rotorua, New Zealand, 3010
      • Gdansk, Poland, 80-214
        • Recruiting
        • UNIWERSYTECKIE CENTRUM KLINICZNE (Site #1401)
        • Contact:
      • Gliwice, Poland, 44-102
        • Recruiting
        • Centrum Onkologii-Instytut im.M.Sklodowskiej Curie (Site # 1405)
        • Contact:
      • Katowice, Poland, 40-519
        • Recruiting
        • Pratia Onkologia Katowice (Site #1403)
        • Contact:
      • Konin, Poland, 62-500
        • Recruiting
        • Przychodnia Lekarska Komed (Site #1407)
        • Contact:
      • Krakow, Poland, 31-826
        • Recruiting
        • Szpital Specjalistyczny im. L.Rydygiera w Krakowie (Site #1404)
        • Contact:
      • Siedlce, Poland, 08-110
        • Recruiting
        • Mazowiecki Szpital Wojewódzki im. sw. Jana Pawla II w Siedlcach Sp. z o.o. (Site #1402)
        • Contact:
      • Warsaw, Poland, 02-781
        • Recruiting
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curiee - Panstwowy Instytut (Site #1406)
        • Contact:
      • Braga, Portugal, 4710-243
        • Recruiting
        • Centro Clínico Académico de Braga (Site #1506)
        • Contact:
      • Coimbra, Portugal
        • Recruiting
        • Instituto Portugues de Oncologia de Coimbra Francisco Gentil, EPE (Site #1503)
        • Contact:
      • Lisbon, Portugal, 1099-023
        • Recruiting
        • Instituto Português de Oncologia Lisboa (Site #1508)
        • Contact:
      • Portimão, Portugal, 8500-338
        • Recruiting
        • Centro Hospitalar Algarve (Site #1501)
        • Contact:
      • Porto, Portugal, 4200-072
        • Recruiting
        • Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE (Site #1505)
        • Contact:
      • Porto, Portugal, 4200-319
        • Recruiting
        • Centro Hospitalar Universitario de Sao Joao (Site #1507)
        • Contact:
      • Senhora da Hora, Portugal, 4464-509
        • Recruiting
        • Unidade Local de Saude de Matosinhos, E.P.E. - Hospital Pedro Hispano (Site #1502)
        • Contact:
      • Vila Nova de Gaia, Portugal, 4434-502
        • Recruiting
        • Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E. (Site # 1504)
        • Contact:
      • Novena, Singapore, 308433
        • Recruiting
        • Tan Tock Seng Hospital (Site # 2902)
        • Contact:
      • Singapore, Singapore, 168583
        • Recruiting
        • National Cancer Centre Singapore (Site # 2901)
        • Contact:
      • Busan, South Korea, 49267
        • Recruiting
        • Kosin University Gospel Hospital (Site # 2707)
        • Contact:
      • Goyang-si, South Korea, 10408
        • Recruiting
        • National Cancer Center (Site # 2704)
        • Contact:
      • Hwasun, South Korea, 58128
        • Recruiting
        • Chonnam National University Hwasun Hospital (Site # 2705)
        • Contact:
      • Seongnam, South Korea, 13620
        • Recruiting
        • Seoul National University Bundang Hospital (Site # 2706)
        • Contact:
      • Seoul, South Korea, 3080
        • Recruiting
        • Seoul National University Hospital (Site # 2701)
        • Contact:
      • Seoul, South Korea, 3722
        • Recruiting
        • SEVERANCE HOSPITAL, YONSEI UNIVERSITY (Site # 2702)
        • Contact:
      • Seoul, South Korea, 6351
        • Recruiting
        • Samsung Medical Center (Site # 2703)
        • Contact:
      • Badalona, Spain, 8916
        • Recruiting
        • ICO Badalona - Hospital Universitari Germans Trias i Pujol (Site # 1311)
        • Contact:
      • Barcelona, Spain, 08035
        • Recruiting
        • Hospital Universitari Vall d'Hebron (Site #1301)
        • Contact:
      • Barcelona, Spain, 08036
        • Recruiting
        • Hospital Clinic de Barcelona (Site #1305)
        • Contact:
      • Barcelona, Spain, 08041
        • Recruiting
        • Hospital de la Santa Creu I Sant Pau Site #1304
        • Contact:
      • Barcelona, Spain, 08908
        • Recruiting
        • Institut Catala d'Oncologia (Site # 1302)
        • Contact:
      • Madrid, Spain, 28027
        • Recruiting
        • Clinica Universidad de Navarra- Madrid (Site #1310)
        • Contact:
      • Madrid, Spain, 28041
        • Recruiting
        • Hospital Universitario 12 De Octubre (Site #1303)
        • Contact:
      • Pamplona, Spain, 31008
        • Recruiting
        • Clinica Universidad de Navarra (Site #1306)
        • Contact:
      • Santander, Spain, 39008
        • Recruiting
        • Hospital Universitario Marques de Valdecilla (HUMV) (Site #1309)
        • Contact:
      • Valencia, Spain, 46010
        • Recruiting
        • Hospital Clinico Universitario de Valencia (Site #1307)
        • Contact:
      • Valencia, Spain, 46014
        • Recruiting
        • Hospital General Universitario de Valencia (Site #1308)
        • Contact:
      • Fribourg, Switzerland, 1752
        • Recruiting
        • HFR Fribourg Kantonsspital Fribourg (Site # 1803)
        • Contact:
      • Geneva, Switzerland, 1205
        • Recruiting
        • Hopitaux Universitaires de Geneve (Site # 1802)
        • Contact:
      • Lausanne, Switzerland, 1011
        • Recruiting
        • Centre Hospitalier Universitaire Vaudois (CHUV) (Site # 1801)
        • Contact:
      • Changhua, Taiwan, 50006
        • Recruiting
        • Changhua Christian Medical Foundation Changhua Christian Hospital (Site # 2602)
        • Contact:
      • Kaohsiung City, Taiwan, 807
        • Recruiting
        • Kaohsiung Medical University Chung-Ho Memorial Hospital (Site # 2601)
        • Contact:
      • Taichung, Taiwan, 40447
        • Recruiting
        • China Medical University Hospital (CMUH) (Site # 2603)
        • Contact:
      • Taipei, Taiwan, 10002
        • Recruiting
        • National Taiwan University Hospital (Site # 2604)
        • Contact:
      • Bangkok, Thailand, 10400
        • Recruiting
        • Phramongkutklao Hospital (Site # 2505)
        • Contact:
      • Bangkok, Thailand, 10400
        • Recruiting
        • Rajavithi Hospital (Site # 2504)
        • Contact:
      • Chiang Mai, Thailand, 50200
        • Recruiting
        • Maharaj Nakorn Chiang Mai Hospital (Site # 2506)
        • Contact:
      • Dusit, Thailand, 10300
      • Hat Yai, Thailand, 90110
        • Recruiting
        • Songklanagarind Hospital (Site # 2502)
        • Contact:
      • Ankara, Turkey (Türkiye), 6100
        • Recruiting
        • Hacettepe University Medical Faculty (Site # 1201)
        • Contact:
      • Ankara, Turkey (Türkiye), 6520
        • Recruiting
        • Memorial Ankara Hospital (Site # 1202)
        • Contact:
      • Antalya, Turkey (Türkiye), 7020
        • Recruiting
        • Memorial Antalya Hastanesi (Site # 1204)
        • Contact:
      • Istanbul, Turkey (Türkiye), 34098
        • Recruiting
        • Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty (Site # 1203)
        • Contact:
      • Izmir, Turkey (Türkiye), 35330
        • Recruiting
        • Dokuz Eylul University Medical School (Site # 1206)
        • Contact:
      • Aberdeen, United Kingdom, AB25 2ZN
        • Recruiting
        • Aberdeen Royal Infirmary (Site #0504)
        • Contact:
      • Birmingham, United Kingdom, B15 2TH
        • Recruiting
        • University Hospitals Birmingham (Queen Elizabeth Hospital) (Site #0512)
        • Contact:
      • Cambridge, United Kingdom, CB2 0QQ
        • Recruiting
        • Cambridge University Hospitals (Site #0513)
        • Contact:
      • Glasgow, United Kingdom, G12 0YN
        • Recruiting
        • Beatson West of Scotland Cancer Centre (Site # 0510)
        • Contact:
      • Leeds, United Kingdom, LS9 7TF
        • Recruiting
        • St James University Hospital Leeds (Site #0511)
        • Contact:
      • Liverpool, United Kingdom, L7 8YA
        • Recruiting
        • Clatterbridge Cancer Center NHS Foundation (Site #0507)
        • Contact:
      • London, United Kingdom, SW3 6JJ
        • Recruiting
        • Royal Marsden Hospital - Chelsea (Site #0505)
        • Contact:
      • London, United Kingdom, WC1E 6AG
        • Recruiting
        • University College London Hospital (Site #0502)
        • Contact:
      • Manchester, United Kingdom, M20 4BX
        • Recruiting
        • The Christie Hospital (Site #0508)
        • Contact:
      • Middlesex, United Kingdom, HA6 2RN
        • Recruiting
        • Mount Vernon Cancer Centre (Site #0506)
        • Contact:
      • Newcastle upon Tyne, United Kingdom, NE7 7DN
        • Recruiting
        • Newcastle University (Site # 509)
        • Contact:
      • Nottingham, United Kingdom, NG5 1PB
        • Recruiting
        • Nottingham University Hospitals City Campus (Site #0503)
        • Contact:
      • Oxford, United Kingdom, OX3 7LE
      • Portsmouth, United Kingdom, PO6 3LY
        • Recruiting
        • Queen Alexandra Hospital (Site # 0514)
        • Contact:
      • Sutton, United Kingdom, SM2 5PT
        • Recruiting
        • Royal Marsden Hospital- London (Site # 0501)
        • Contact:
    • Alabama
      • Birmingham, Alabama, United States, 35233
        • Recruiting
        • University of Alabama Hospital (Site # 0137)
        • Contact:
    • Arizona
      • Phoenix, Arizona, United States, 85054
        • Recruiting
        • Mayo Clinic Hospital (Site #0147)
        • Contact:
    • California
      • La Jolla, California, United States, 92093
        • Recruiting
        • UC San Diego Moores Cancer Center (Site #0107)
        • Contact:
      • Los Angeles, California, United States, 90095
        • Recruiting
        • UCLA Department of Medicine - Hematology/Oncology (Site #0106)
        • Contact:
      • Sacramento, California, United States, 95817
      • San Francisco, California, United States, 94143
        • Recruiting
        • University of California San Francisco (Site #0130)
        • Contact:
      • Stanford, California, United States, 94305
        • Recruiting
        • Stanford Cancer Institute (Site #0150)
        • Contact:
    • Colorado
      • Aurora, Colorado, United States, 80012
        • Recruiting
        • Rocky Mountain Cancer Centers, LLP (Site #0122)
        • Contact:
      • Aurora, Colorado, United States, 80045
        • Recruiting
        • Rocky Mountain Regional VAMC (Site #0124)
        • Contact:
      • Aurora, Colorado, United States, 80045
        • Recruiting
        • University of Colorado Cancer Center (UCCC) - Anschutz Medical Campus (Site#0121)
        • Contact:
    • Delaware
      • Newark, Delaware, United States, 19713
        • Recruiting
        • ChristianaCare Helen F. Graham Cancer Center and Research Institute (Site # 127)
        • Contact:
    • Florida
      • Jacksonville, Florida, United States, 32224
        • Recruiting
        • Mayo Clinic Florida (Site #0148)
        • Contact:
      • Palm Bay, Florida, United States, 32901
        • Recruiting
        • Cancer Care Centers of Brevard (Site #0136)
        • Contact:
      • Tampa, Florida, United States, 33612
        • Recruiting
        • Moffit Cancer Center (Site #0105)
        • Contact:
    • Illinois
      • Chicago, Illinois, United States, 60064
        • Recruiting
        • Captain James A Lovell Federal Health Care Center-VA North Chicago (Site # 133)
        • Contact:
    • Iowa
      • Iowa City, Iowa, United States, 52242
        • Recruiting
        • University of Iowa Hospitals & Clinics (Site#0140)
        • Contact:
    • Kansas
      • Westwood, Kansas, United States, 66205
        • Recruiting
        • University of Kansas Medical Center Research Institute, Inc. (Site #0149)
        • Contact:
    • Kentucky
      • Lexington, Kentucky, United States, 40536
        • Recruiting
        • University of Kentucky, Markey Cancer Center (Site # 109)
        • Contact:
      • Louisville, Kentucky, United States, 40202
        • Recruiting
        • Norton Cancer Institute (Site#0111)
        • Contact:
      • Louisville, Kentucky, United States, 40202
        • Recruiting
        • The University of Louisville, James Graham Brown Cancer Center (Site#0115)
        • Contact:
    • Maryland
      • Baltimore, Maryland, United States, 21201
        • Recruiting
        • University of Maryland Medical Group (Site #0112)
        • Contact:
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Recruiting
        • Massachusetts General Hospital (Site #0131)
        • Contact:
      • Boston, Massachusetts, United States, 02136
        • Recruiting
        • Dana-Farber Cancer Institute (Site#0101)
        • Contact:
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • Recruiting
        • University of Michigan (Site # 161)
        • Contact:
    • Minnesota
      • Maplewood, Minnesota, United States, 55109
      • Rochester, Minnesota, United States, 55905
        • Recruiting
        • Mayo Clinic Cancer Center - Rochester (Site #0146)
        • Contact:
    • Missouri
      • St Louis, Missouri, United States, 63110
        • Recruiting
        • Washington University School of Medicine (Site #0114)
        • Contact:
    • New Jersey
      • Hackensack, New Jersey, United States, 07601
        • Recruiting
        • Hackensack Meridian Health (Site # 119)
        • Contact:
      • Newark, New Jersey, United States, 07103
        • Recruiting
        • Rutgers- Cancer Institute (Site #0145)
        • Contact:
    • New York
      • New York, New York, United States, 10003
      • New York, New York, United States, 10021
        • Recruiting
        • Memorial Sloan Kettering Cancer Center (Site#0142)
        • Contact:
    • North Carolina
      • Durham, North Carolina, United States, 27703
        • Recruiting
        • Duke University Health System (Site#0118)
        • Contact:
    • Ohio
      • Canton, Ohio, United States, 44708
      • Cincinnati, Ohio, United States, 45221
        • Recruiting
        • University of Cincinnati Cancer Institute (Site#0117)
        • Contact:
      • Cleveland, Ohio, United States, 44106
        • Recruiting
        • University Hospitals Seidman Cancer Center (Site #0151)
        • Contact:
      • Cleveland, Ohio, United States, 44195
    • Oregon
      • Portland, Oregon, United States, 97213
        • Recruiting
        • Providence Portland Medical Center (Site #0113)
        • Contact:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15206
        • Recruiting
        • UPMC Hillman Cancer Center (Site #0103)
        • Contact:
      • Pittsburgh, Pennsylvania, United States, 15240
        • Recruiting
        • VA Pittsburgh Healthcare System (Site #0123)
        • Contact:
    • Rhode Island
      • Providence, Rhode Island, United States, 02903
        • Recruiting
        • Lifespan Cancer Institute (Site #0132)
        • Contact:
    • South Carolina
      • Charleston, South Carolina, United States, 29425
        • Recruiting
        • Medical University of South Carolina (MUSC) (Site#0104)
        • Contact:
    • Tennessee
      • Nashville, Tennessee, United States, 37203
        • Recruiting
        • SCRI-Oncology Partners (Site#0126)
        • Contact:
      • Nashville, Tennessee, United States, 37232
        • Recruiting
        • Vanderbilt-Ingram Cancer Center (Site #0116)
        • Contact:
    • Texas
      • Houston, Texas, United States, 77005
        • Recruiting
        • MD Anderson Cancer Center (Site#0102)
        • Contact:
      • Waco, Texas, United States, 676712
        • Recruiting
        • SCRI- Texas Oncology- Central South (Site #0152)
        • Contact:
    • Virginia
      • Charlottesville, Virginia, United States, 22904
        • Recruiting
        • University of Virginia (Site#0134)
        • Contact:
      • Richmond, Virginia, United States, 23219
        • Recruiting
        • Virginia Commonwealth University (VCU) Massey Cancer Center (Site #0129)
        • Contact:
      • Richmond, Virginia, United States, 23249
        • Recruiting
        • Richmond Department of Veterans Affairs (Site #0138)
        • Contact:
    • Washington
      • Edmonds, Washington, United States, 98026
        • Recruiting
        • Swedish Cancer Institute - North Campus Edmonds (Site # 0160)
        • Contact:
      • Seattle, Washington, United States, 98104
        • Recruiting
        • Swedish Cancer Institute (Site # 0159)
        • Contact:
      • Seattle, Washington, United States, 98109
        • Recruiting
        • University of Washington - Seattle Cancer Care Alliance (Site #0125)
        • Contact:
      • Vancouver, Washington, United States, 98684
        • Recruiting
        • Northwest Cancer Specialists, PC (Site#0120)
        • Contact:
    • Wisconsin
      • Madison, Wisconsin, United States, 53705
        • Recruiting
        • William S. Middleton Memorial Veteran's Hospital (Site #0141)
        • Contact:
      • Madison, Wisconsin, United States, 53792
        • Recruiting
        • University of Wisconsin Hospital and Clinics (Site #0157)
        • Contact:
      • Milwaukee, Wisconsin, United States, 53233
        • Recruiting
        • Advocate Aurora Research Institute (Site # 0153)
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥18 years on the day the Informed Consent Form is signed.
  • Histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: primary tumor location of paranasal sinuses and nasopharynx, any histology are excluded.
  • No prior systemic therapy administered in the R or M setting; and completed systemic therapy >6 months prior if given as part of multimodal treatment for locoregionally advanced disease in the adjuvant or definitive setting.
  • Archival tumor tissue or willing to undergo pretreatment biopsy at Screening if archival tissue is insufficient or unavailable.
  • PD-L1 CPS ≥1.
  • Measurable disease based on RECIST 1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate organ function, as defined in the protocol.

Exclusion Criteria:

  • Disease suitable for local therapy administered with curative intent.
  • Prior treatment with anti-TGFβ therapy.
  • Prior therapy with an anti-EGFR antibody (exception: radio sensitizing agents and multimodal treatment for locoregionally advanced disease).
  • Prior history of Grade ≥2 intolerance or hypersensitivity reaction to anti-EGFR therapy or other murine proteins.
  • Prior therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.
  • Progressive disease <6 months from completion of curative intent systemic therapy for locoregionally advanced HNSCC.
  • Life expectancy less than 3 months.
  • Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, or leptomeningeal disease are excluded.
  • Current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment.
  • Subject participated in another clinical study or received treatment with another investigational drug must wait at least 5 half-lives of the treatment received or 4 weeks (whichever is shorter) following prior therapy.
  • Active autoimmune disease requiring systemic treatment in the past 2 years.
  • Subjects with chronic hepatitis B virus (HBV) infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment.
  • Subjects with a known history of hepatitis C virus (HCV) who have not completed curative antiviral treatment or have an HCV viral load above the limit of quantification at Screening.
  • Known history of human immunodeficiency virus (HIV).
  • Receipt of any organ transplantation, including autologous and allogeneic stem cell transplantation, with the exception of transplants that do not require immunosuppression.
  • Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer.
  • Any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days prior to the first dose of study treatment, except for topical, intranasal, intrabronchial, or ocular steroids.
  • Use of a live or live attenuated vaccine within 4 weeks prior to Screening.

Other Inclusion/Exclusion criteria may apply as defined in the protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Phase 2 Arm A

ficerafusp alfa 1500 mg QW + pembrolizumab 200 mg every 3 weeks (Q3W)

Investigational

Immunotherapy agent used in combination with investigational agent

Experimental: Phase 2 Arm B

ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W

Investigational

Immunotherapy agent used in combination with investigational agent

Placebo Comparator: Phase 2 Arm C

placebo QW + pembrolizumab 200 mg Q3W

Immunotherapy agent used in combination with investigational agent

Placebo Control

Experimental: Phase 3 OBD Arm

ficerafusp alfa OBD + pembrolizumab 200 mg Q3W

Investigational

Immunotherapy agent used in combination with investigational agent

Placebo Comparator: Phase 3 Arm C

placebo QW + pembrolizumab 200 mg Q3W

Immunotherapy agent used in combination with investigational agent

Placebo Control

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Phase 2 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.
Time Frame: Up to 30 days post end of treatment for TEAEs (90 days for SAEs).

To assess safety and tolerability of ficerafusp alfa with pembrolizumab.

Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
Phase 2 - Objective Response Rate (ORR) per RECIST 1.1 by blinded independent central review (BICR)
Time Frame: Approximately 1 year.

ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.

Approximately 1 year.
Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.
Time Frame: Approximately 2 years.

ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.

Approximately 2 years.
Phase 3 - Overall Survival (OS)
Time Frame: Approximately 3 years.

OS: Defined as the time from the randomization to death due to any cause.

Approximately 3 years.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Phase 2 - Duration of Response (DOR) per RECIST 1.1 by BICR.
Time Frame: Approximately 1 year.

DOR: For subjects who demonstrated CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death, whichever occurs first, per RECIST 1.1 by BICR.

Approximately 1 year.
Phase 3 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.
Time Frame: Up to 30 days post end of treatment for TEAEs (90 days for SAEs).

To assess safety and tolerability of ficerafusp alfa with pembrolizumab.

Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
Phase 3 - Progression-free survival (PFS) per RECIST 1.1 by BICR.
Time Frame: Approximately 3 years.

PFS: Defined as the time from randomization to the first documented PD per RECIST 1.1 as determined by BICR or death due to any cause, whichever occurs first.

Approximately 3 years.
Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.
Time Frame: Approximately 3 years.

ORR: Defined as confirmed CR + PR per RECIST 1.1 by BICR. (FAS).

Approximately 3 years.
Phase 3 - Duration of Response (DOR) per RECIST 1.1 by BICR.
Time Frame: Approximately 3 years.

DOR: For subjects who demonstrated CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death, whichever occurs first per RECIST 1.1 by BICR.

Approximately 3 years.
Phase 3 - Clinical Benefit Rate (CBR) per RECIST 1.1 by BICR.
Time Frame: Approximately 3 years.

Clinical Benefit Rate: For subject who demonstrated CR + PR + SD>6 months per RECIST 1.1 by BICR.

Approximately 3 years.
Phase 3 - ORR, per RECIST 1.1 by investigator's assessment.
Time Frame: Approximately 3 years.

ORR, per RECIST 1.1 as determined by investigator's assessment.

Approximately 3 years.
Phase 3 - DOR, per RECIST 1.1 by investigator's assessment.
Time Frame: Approximately 3 years.

DOR, per RECIST 1.1 as determined by investigator's assessment.

Approximately 3 years.
Phase 3 - PFS, per RECIST 1.1 by investigator's assessment.
Time Frame: Approximately 3 years.

PFS, per RECIST 1.1 as determined by investigator's assessment.

Approximately 3 years.
Phase 3 - 14. Time to deterioration (TTD) in global health status measured by the EORTC QLQ C30 items for global health status and quality of life scale (item 29/30)
Time Frame: Approximately 3 years.

To evaluate TTD in global health status/quality of life in subjects treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab.

TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline in QoL using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 Item 30) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher value indicates a better level of function.

Approximately 3 years.
Phase 3 - Time to deterioration (TTD) in pain measured by the EORTC HN 35 (items 31-34) pain domain.
Time Frame: Approximately 3 years.

To evaluate TTD in pain in subjects treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab.

TTD defined as the time from first dose (baseline) to change in pain score by 10-point from baseline, using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core Head and Neck Module (EORTC HN35). A higher score indicates a higher level of symptom burden.

Approximately 3 years.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 28, 2025

Primary Completion (Estimated)

April 1, 2028

Study Completion (Estimated)

July 1, 2029

Study Registration Dates

First Submitted

January 10, 2025

First Submitted That Met QC Criteria

January 17, 2025

First Posted (Actual)

January 23, 2025

Study Record Updates

Last Update Posted (Actual)

October 29, 2026

Last Update Submitted That Met QC Criteria

October 28, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.